Wider adoption of the autologous cultured cartilage JACC procedure and expansion of certified facilities authorized to perform it
First written in FY2016. 26 of 33 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-10-30.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Following the expanded indication for osteoarthritis of the knee, we will focus on expanding sales at existing facilities to achieve 350 cases in the fiscal year ending March 2027, then expand into new facilities to substantially increase this to 600 cases in the fiscal year ending March 2028.」
The company set specific JACC sales targets of 350 cases for the fiscal year ending March 2027 and 600 cases for the fiscal year ending March 2028 following the expanded indication for osteoarthritis of the knee. - FY2025AdvancedAnnual report
「Sales increased as a result of sales activities highlighting JACC's efficacy, including seminars held in conjunction with the Japanese Knee Society, in addition to the increase in reimbursement prices under the FY2024 revision of medical fees.」
The company highlighted JACC's efficacy through higher reimbursement prices and seminars held alongside an academic conference, contributing to higher sales. - FY2025-H1AdvancedAnnual report
「Sales in the cartilage business, JACC (autologous cultured cartilage), for the first six months were ¥202.544 million, up 24.7% year on year. Demand increased at medical institutions where demand had declined during the COVID-19 pandemic, driving sales growth. Steady sales activities highlighting JACC's efficacy also steadily increased awareness among knee specialists. In addition, the increase in reimbursement prices from June under the FY2024 revision of medical fees contributed to higher sales.」
JACC sales increased 24.7% year on year as demand recovered at medical institutions where it had declined during the COVID-19 pandemic, supported by sales activities highlighting efficacy and increased awareness among knee specialists. - FY2024Delayed recovery in orders from large facilities and a policy of expanding core facilitiesAnnual report
「JACC sales for the fiscal year were ¥320.508 million, down 13.8% year on year. Although orders from medical institutions whose orders had ceased during the COVID-19 pandemic and from new facilities remained firm, orders from the large facilities driving JACC sales did not recover. The main factor was that the medical institutions to which the transferred physicians moved did not meet the facility requirements, and recovery in orders is taking time.」
Sales recovery was delayed by physician transfers at large facilities and facility requirements, resulting in a 13.8% year-on-year decline in full-year sales. Meanwhile, the company indicated a policy of supporting growth by highlighting the evidence and expanding core facilities. - FY2024-Q3Continued weakness at large facilities and delayed recovery due to physician transfersAnnual report
「JACC sales for the period were ¥235.746 million, down 20.2% year on year. Orders from medical institutions whose orders had ceased during the COVID-19 pandemic and from new facilities remained firm, but large facilities that drive JACC sales continued to post weak results. The impact of physician transfers was significant, and recovery in sales will take time. Meanwhile, numerous reports on JACC were presented at the Japanese Knee Society meeting held in December, demonstrating its efficacy in joint-preserving treatment. We will continue to implement effective sales initiatives that highlight the evidence.」
Although orders from new facilities and medical institutions whose orders had ceased remained firm, sales declined 20.2% year on year due to the impact of physician transfers at large facilities, and the company stated that recovery would take time. It will continue to highlight the evidence based on conference reports. - FY2024-Q2Continued sales decline due to physician transfers at large facilities, with signs of recoveryAnnual report
「JACC sales for the period were ¥162.451 million, down 20.8% year on year. Although orders from medical institutions whose orders had ceased during the COVID-19 pandemic and from new facilities increased, the impact of physician transfers at large facilities driving JACC sales was significant, and sales did not recover. Meanwhile, major orthopaedic conferences saw an increase in reports of favourable clinical outcomes, providing support from an evidence standpoint. Orders from large facilities are gradually beginning to recover, and we will implement effective sales initiatives to capitalise on this opportunity.」
Sales declined 20.8% year on year due to physician transfers at large facilities. The company noted increased orders from existing and new facilities, a recovery in orders from large facilities and conference reports on clinical outcomes. - FY2024-Q1Decline in sales due to physician transfers at large facilities and progress in new ordersAnnual report
「JACC sales for the period were ¥72.643 million, down 29.2% year on year. In the first quarter, sales struggled at large facilities that drive sales, affected by the transfer of physicians experienced in using JACC, among other factors. On the other hand, repeat orders from medical institutions whose orders had ceased during the COVID-19 pandemic and orders from new facilities increased.」
JACC sales declined 29.2% year on year due to the transfer of physicians experienced in using JACC at large facilities, while repeat orders from medical institutions whose orders had ceased and orders from new facilities increased. - FY2023-Q3AdvancedAnnual report
「JACC sales for the period were ¥295.412 million, up 4.6% year on year. Orders from core facilities, which are major customers, remained firm, increasing sales year on year. On the other hand, orders from other general facilities slowed, and the company is strengthening promotional activities.」
Orders from core facilities remained firm, increasing JACC sales by 4.6% year on year. The company also noted a slowdown in orders from general facilities and efforts to strengthen promotional activities. - FY2023-Q2AdvancedAnnual report
「JACC sales for the period were ¥205.037 million, up 17.0% year on year. Although a succession of surgeries was cancelled due to the seventh wave, sales increased year on year as orders from facilities that had previously held back on using JACC and from large facilities recovered substantially.」
Orders from facilities that had held back on using JACC and from large facilities recovered, increasing JACC sales by 17.0% year on year. - FY2023-Q1AdvancedAnnual report
「JACC sales for the period were ¥102.579 million, up 26.3% year on year. Restrictions on visits to medical institutions and the holding of academic conferences related to COVID-19 were eased, and we resumed sales activities while carefully assessing conditions. As a result, orders recovered from facilities that had held back on using JACC because of COVID-19, while orders from large facilities returned to pre-COVID-19 levels, increasing sales year on year.」
The resumption of sales activities led to a recovery in orders from facilities that had held back on using JACC, while orders from large facilities returned to pre-COVID-19 levels. The company described specific progress in the recovery of JACC adoption and orders. - FY2022AdvancedAnnual report
「JACC sales for the fiscal year were ¥385.993 million, up 16.3% year on year. Although conditions were difficult, with in-person sales activities suspended because of COVID-19 and the number of surgeries declining at individual facilities, orders from large facilities recovered from the second quarter onward, and orders from new facilities also increased, resulting in higher full-year sales than in the previous year.」
Despite continuing restrictions related to COVID-19, the recovery in orders from large and new facilities increased full-year JACC sales by 16.3% year on year. - FY2022-Q3AdvancedAnnual report
「JACC sales for the first nine months were ¥282.436 million, up 8.5% year on year. In-person academic conferences and study meetings have gradually become more common. Contacts with physicians also increased, and approaches to new facilities proved successful in addition to stable orders from large facilities. Orders also resumed from facilities that had temporarily suspended use of JACC, resulting in higher sales than in the same period of the previous year.」
Stable orders from large facilities, approaches to new facilities and the resumption of orders from facilities that had temporarily suspended use of JACC increased sales by 8.5% year on year. - FY2022-Q2AdvancedAnnual report
「JACC sales for the first six months were ¥175.222 million, down 4.7% year on year. Although it took time to expand orders from some existing facilities and overall sales declined from the same period of the previous year, the company secured more orders from new facilities than in the first quarter by enhancing promotional materials, using online tools and devising ways to provide information while restrictions on sales activities at medical institutions remained in place.」
JACC sales declined 4.7% year on year as it took time to expand orders from existing facilities, while the company secured more orders from new facilities than in the first quarter by using promotional materials and online tools. - FY2022-Q1RestatedAnnual report
「JACC sales for the first quarter were ¥81.225 million, down 0.4% year on year. Although conditions remained difficult, with visits to medical institutions for sales activities having to be suspended, sales were maintained at approximately the previous year's level through continued efforts to raise awareness of JACC and provide information on the usefulness of collagen membranes using online tools.」
The company continued its policy of promoting JACC and raising awareness, providing information through online tools. Sales were approximately at the previous year's level. - FY2020AdvancedAnnual report
「JACC sales for the fiscal year were ¥416.599 million, up 11.8% year on year. Simplifying the transplantation procedure by using a collagen membrane instead of the patient's own periosteum, following partial approval for the change obtained in January 2019, increased orders from heavy users. Sales also increased year on year as we pursued new customers and secured orders from medical institutions that had not previously placed orders.」
Simplifying the procedure through the use of a collagen membrane and developing new customers increased JACC sales by 11.8% year on year, and orders were secured from medical institutions that had not previously placed orders. - FY2020-Q3AdvancedAnnual report
「Approval obtained in January 2019 for the use of a collagen membrane in place of the patient's own periosteum simplified the transplantation procedure, among other factors, driving an increase in orders from new facilities.」
The company stated that specification changes to make JACC less invasive and simplify the transplantation procedure led to an increase in orders from new facilities. - FY2019-Q3AdvancedAnnual report
「As of the end of December, JACC could be used at 303 medical institutions with registered use, an increase of 5 from the end of September, and 1,552 physicians had completed the training course, an increase of 31 from the end of September.」
The number of facilities with registered use of JACC increased to 303, and the number of physicians who had completed the training course reached 1,552. - FY2019-Q2AdvancedAnnual report
「As of the end of September, JACC could be used at 298 medical institutions with registered use, an increase of 7 from the end of March, and 1,521 physicians had completed the training course, an increase of 72 from the end of March.」
The number of facilities with registered use of JACC increased from 291 at the end of March to 298, while the number of physicians who had completed the training course increased from 1,449 to 1,521. - FY2019-Q1AdvancedAnnual report
「As of the end of June 2018, the number of medical institutions with registered use of JACC had increased to 295. However, sales declined slightly year on year, affected by delays in adapting to less-invasive procedures and simplified transplantation techniques and by insufficient awareness among potential patients.」
The number of facilities with registered use of JACC increased from 291 to 295. However, sales declined slightly year on year because of delays in adapting to less-invasive procedures and simplified transplantation techniques and insufficient awareness among potential patients. - FY2018AdvancedAnnual report
「As of the end of March 2018, the number of medical institutions certified to use JACC had increased steadily to 291 nationwide, and the number of physicians performing the procedure had reached 1,448.」
The number of certified JACC facilities increased to 291, and the number of physicians performing the procedure reached 1,448. - FY2018-Q3AdvancedAnnual report
「As of the end of December 2017, the number of medical institutions with registered use of JACC had reached 280 and was continuing to increase steadily. However, because JACC had not yet gained sufficient acceptance among patients, we were unable to build sufficient orders from new facilities.」
The number of facilities with registered use of JACC increased from 271 at the end of September 2017 to 280. However, orders from new facilities did not build sufficiently because JACC had not gained sufficient acceptance among patients. - FY2018-Q2AdvancedAnnual report
「As a result of sales activities, as of the end of September 2017, JACC could be used at 271 medical institutions with registered use. Although the number was steadily increasing, we were unable to build sufficient orders from new medical institutions.」
The company reported 271 registered-use facilities as of the end of September 2017. Although the number of facilities increased, orders from new medical institutions did not build sufficiently. - FY2018-Q1AdvancedAnnual report
「As of the end of June 2017, JACC could be used at 267 medical institutions, of which 121 had performed transplant procedures.」
The number of facilities certified to use JACC increased from 252 at the end of December 2016 to 267, and the company also disclosed the number of medical institutions with a track record of performing transplants. - FY2017-Q3AdvancedAnnual report
「As of the end of December 2016, the number of medical institutions certified to use JACC had reached 252, and JACC was available in all prefectures.」
The number of facilities certified to use JACC increased from 236 at the end of the previous quarter to 252. - FY2017-Q2AdvancedAnnual report
「As of the end of September 2016, the number of medical institutions certified to use JACC had reached 236, and JACC was available in all prefectures.」
The number of certified facilities increased from 226 at the end of the previous quarter to 236. - FY2017-Q1AdvancedAnnual report
「As of the end of June 2016, the number of medical institutions certified to use JACC had reached 226, and JACC was available in all prefectures. In addition to educational activities for healthcare professionals, we began activities to raise awareness among the general patient population of autologous cultured cartilage transplantation, the treatment method using JACC, and in April 2016 launched a dedicated website featuring a professional football player who had undergone the procedure.」
The number of certified facilities increased from 218 at the end of the previous fiscal year to 226, and a dedicated website was launched to raise awareness among patients. - FY2016First statedAnnual report
「We will continue to work to expand the number of facilities certified to use JACC and increase sales of JACC.」
The company was providing training to medical institutions and physicians performing the procedure, and stated that JACC could be used at 218 facilities across all prefectures as of the end of March 2016.